Effect of plaunotol in combination with clarithromycin or amoxicillin on Helicobacter pylori in vitro and in vivo

被引:26
作者
Koga, T [1 ]
Inoue, H [1 ]
Ishii, C [1 ]
Okazaki, Y [1 ]
Domon, H [1 ]
Utsui, Y [1 ]
机构
[1] Sankyo Co Ltd, Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
关键词
D O I
10.1093/jac/dkf094
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Plaunotol, a cytoprotective anti-ulcer agent, has antibacterial activity against Helicobacter pylori. The purpose of the present study was to investigate the effect of plaunotol when combined with clarithromycin or amoxicillin against H. pylori. When combined with clarithromycin, plaunotol showed synergic activity against 11 of 14 strains, and additive activity against the other three strains, by chequerboard titration. When combined with amoxicillin, plaunotol showed additive activity against 10 of 14 strains. No antagonistic effects were seen against any of the strains tested. The interactions between plaunotol and either clarithromycin or amoxicillin were determined by time-kill assay against the Sydney Strain (strain SS1) of H. pylori. The combination of plaunotol with clarithromycin showed synergic activity and with amoxicillin showed additive activity. In a C57BL/6 mouse gastritis model infected with H. pylori SS1, the plaunotol-clarithromycin and plaunotol-amoxicillin combinations both exhibited synergic effects, which allowed the effective dose of clarithromycin to be reduced when co-administered with plaunotol. These results suggest that plaunotol may have a useful role in combination with anti-H. pylori drugs in the treatment of H. pylori-associated diseases.
引用
收藏
页码:133 / 136
页数:4
相关论文
共 10 条
[1]   Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods [J].
Bajaksouzian, S ;
Visalli, MA ;
Jacobs, MR ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :1973-1976
[2]  
Eliopolous GM., 1996, Antibiotics in laboratory medicine, P330
[3]   The importance of clarithromycin dose in the management of Helicobacter pylori infection:: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole [J].
Huang, JQ ;
Hunt, RH .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (06) :719-729
[4]   In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori [J].
Koga, T ;
Kawada, H ;
Utsui, Y ;
Domon, H ;
Ishii, C ;
Yasuda, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (05) :919-929
[5]   Interactions of plaunotol with bacterial membranes [J].
Koga, T ;
Watanabe, H ;
Kawada, H ;
Takahashi, K ;
Utsui, Y ;
Domon, H ;
Ishii, C ;
Narita, T ;
Yasuda, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :133-140
[6]  
KOMAI T, 1985, PROG MED S1, V5, P849
[7]  
Lorian V., 1986, ANTIBIOTICS LABORATO, P537
[8]   Comparison of the efficacy of 400 mg and 800 mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population [J].
Miwa, H ;
Murai, T ;
Sato, K ;
Ohkura, R ;
Yamada, T ;
Nagahara, A ;
Ohtaka, K ;
Minowa, T ;
Kurosawa, A ;
Sato, N .
JOURNAL OF GASTROENTEROLOGY, 2000, 35 (07) :536-539
[9]   CURE OF DUODENAL-ULCER ASSOCIATED WITH ERADICATION OF HELICOBACTER-PYLORI [J].
RAUWS, EAJ ;
TYTGAT, GNJ .
LANCET, 1990, 335 (8700) :1233-1235
[10]  
SHIMOYAMA T, 1995, EUROPEAN J GASTRO S1, V7, pS45